UPDATE 1-UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Nuvalent, Inc. Class A
GlaxoSmithKline plc Sponsored ADR

Nuvalent, Inc. Class A

NUVL

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

Adds per share detail in paragraph 2

June 9 (Reuters) - British drugmaker GSK GSK.L on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent NUVL.O for $10.6 billion to boost its lung cancer portfolio.

The all-cash deal values Nuvalent at approximately $124 per share, a 40% premium to its last closing price.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.